Case report: dacomitinib is effective in lung adenocarcinoma with rare egfr mutation l747p and brain metastases

HIGHLIGHTS

• who: Yibin Li from the Zhejiang University City College, China have published the Article: Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases, in the Journal: (JOURNAL) of 14/07/2020
• what: This case demonstrates that a regimen of dacomitinib can achieve significant effects in patients with EGFR L747P mutation after progression on afatinib, especially in those who have brain metastases.

SUMMARY

Predictive biomarkers in advanced non-small-cell lung cancer (NSCLC) include sensitizing epidermal growth factor receptor (EGFR) mutations, ALK rearrangements, ROS1 rearrangements . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.